Status:
COMPLETED
Immune Response Following COVID-19 in Hemodialysis Patients
Lead Sponsor:
AURA Paris
Conditions:
Dialysis; Complications
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD), are at high risk of a severe form of COVID-19. This study aims to characterize the inflammatory and antivi...
Detailed Description
Inclusion criteria were (1) Adult (\>18 years old) patient on HD \> 6 months, and (2) infection by SARS-CoV-2. Diagnosis of COVID-19 was assessed by Reverse-Transcriptase-Polymerase Chain Reaction (RT...
Eligibility Criteria
Inclusion
- Adult (\>18 years old) patient on HD \> 6 months, and
- Infection by SARS-CoV-2. Diagnosis of COVID-19 was assessed by Reverse-Transcriptase-Polymerase Chain Reaction (RT-PCR) for SARS-CoV-2 in nasopharyngeal swab or by typical COVID-19 radiological images on thoracic computerized tomography (CT scan). The date of diagnosis was defined as the day when RT-PCR or CT-scan confirmed the diagnosis.
Exclusion
- Inability to give consent
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2021
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT05307601
Start Date
September 1 2020
End Date
October 30 2021
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AURA Paris
Paris, France, 75014